Blood-Derived clots could protect jaw bone after tooth removal
NCT ID NCT07673848
First seen Jun 29, 2026 · Last updated Sep 02, 2026 · Updated 3 times
Summary
This study investigates whether a patient's own platelet concentrate, called A-PRF, can improve early wound healing after tooth extraction in people at high risk for medication-related osteonecrosis of the jaw (MRONJ). Participants are adults who have taken or are taking bone-strengthening or cancer medications that increase MRONJ risk. The trial uses advanced imaging and protein analysis to track healing over 15 days, with a final check at 180 days.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- autogenous platelet concentrates (A-PRF)
- What this could lead to
- If effective, this approach could reduce the risk of jaw bone death after dental extractions in patients taking bone-strengthening or cancer medications.
- What could go wrong
- This is a small, early-stage study with 44 participants, so results may not apply to all patients. The procedure involves blood draws and centrifugation, and benefits over standard care are not yet proven.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 44 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Nov 2026
An estimate. Start dates often move.
- Expected to finish
-
Dec 2029
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
25 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Eligibility criteria All of the following criteria must be fulfilled for inclusion: * Patient must be willing to read and sign a copy of the Informed Consent Form * Males and females ≥ 25 years old; * Patients who are currently or previously treated with antiresorptive therapy alone or in combination with immune modulators or antiangiogenic medications for the management of cancer; * Patients who are treated with antiresorptive therapy, bisphosphonates, for osteoporosis for more than 5 years; * Patients who have been treated with antiresorptive therapy, bisphosphonates, for osteoporosis for less than 5 years and being concurrently treated with a systemic glucocorticoid; * Patients who are treated with denosumab in the last nine months and being concurrently treated with a systemic glucocorticoid; * Patients who are on the high-risk category to develop MRONJ based on the SDCEP guidance; * Patients who require dental extractions (one per quadrant per patient) of premolar or molar teeth which are irrational to treat for any reason; * Patients with a history of MRONJ. The following patients will be excluded: * Patients with MRONJ at the area of extraction; * Patients with history of radiotherapy in the area of treatment; * Patients with metastatic bone disease in the area of treatment; * Self-reported pregnancy or lactation (this criterion is due to oral tissue changes related to pregnancy and nursing which can affect interpretation of study results); * Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with trial participation or investigational product administration or may interfere with the interpretation of trial results and, in the judgement of the investigator, would make the subject inappropriate for entry into this trial; * Dental extractions in people who are systemically unwell and who require hospital admission; * Patients with poor glycaemic control (uncontrolled diabetes); * Current smokers or smokers who have quit less than 10 years ago (including e-cigarettes)
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Medication-related osteonecrosis of the jaw are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- AI trained to spot dead jawbone on routine dental X-Rays
- New study uses 3D scans to track jaw bone damage from common osteoporosis drugs
- Could a common muscle drug and vitamin e heal jaw bone death?
- Blood concentrate may boost healing of jaw bone damage from common drugs
- Dental implant dilemma: to keep or remove when jaw bone dies?
- Can MRI predict radiation side effects before they happen?